Ariel Investments Has Decreased Viacom (VIAB) Holding By $34.95 Million; Aveo Pharmaceuticals Has 1.32 Sentiment

January 14, 2018 - By Richard Conner

Ariel Investments Llc decreased Viacom Inc. (VIAB) stake by 32.89% reported in 2017Q3 SEC filing. Ariel Investments Llc sold 1.29M shares as Viacom Inc. (VIAB)’s stock declined 19.98%. The Ariel Investments Llc holds 2.64M shares with $73.54M value, down from 3.94M last quarter. Viacom Inc. now has $13.79 billion valuation. The stock increased 9.57% or $2.95 during the last trading session, reaching $33.76. About 12.83M shares traded or 118.36% up from the average. Viacom, Inc. (NASDAQ:VIAB) has declined 8.36% since January 14, 2017 and is downtrending. It has underperformed by 25.06% the S&P500.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $476.18 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Ariel Investments Llc increased U.S. Bancorp (NYSE:USB) stake by 15,823 shares to 377,409 valued at $20.23 million in 2017Q3. It also upped Telenav Inc. (NASDAQ:TNAV) stake by 754,660 shares and now owns 2.98M shares. Johnson & Johnson (NYSE:JNJ) was raised too.

Among 39 analysts covering Viacom Inc. (NASDAQ:VIAB), 12 have Buy rating, 4 Sell and 23 Hold. Therefore 31% are positive. Viacom Inc. had 123 analyst reports since August 7, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of VIAB in report on Wednesday, November 22 with “Hold” rating. Atlantic Securities downgraded the stock to “Underweight” rating in Friday, August 4 report. The firm has “Hold” rating given on Wednesday, February 24 by Topeka Capital Markets. On Monday, November 20 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. Wedbush downgraded the stock to “Neutral” rating in Tuesday, December 13 report. RBC Capital Markets maintained Viacom, Inc. (NASDAQ:VIAB) on Tuesday, August 8 with “Sell” rating. The rating was maintained by RBC Capital Markets on Tuesday, June 6 with “Sell”. The stock has “Neutral” rating by Citigroup on Friday, April 1. The stock of Viacom, Inc. (NASDAQ:VIAB) has “Neutral” rating given on Friday, April 29 by Wedbush. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, June 17.

Analysts await Viacom, Inc. (NASDAQ:VIAB) to report earnings on February, 8 before the open. They expect $1.00 earnings per share, down 3.85% or $0.04 from last year’s $1.04 per share. VIAB’s profit will be $408.50 million for 8.44 P/E if the $1.00 EPS becomes a reality. After $0.77 actual earnings per share reported by Viacom, Inc. for the previous quarter, Wall Street now forecasts 29.87% EPS growth.

Analysts await AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings on March, 28. They expect $-0.03 earnings per share, up 72.73% or $0.08 from last year’s $-0.11 per share. After $-0.02 actual earnings per share reported by AVEO Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>